NCT01980212 is a clinical trial in Advanced Non-small Cell Lung Cancer, sponsored by Hunan Province Tumor Hospital.

Who is sponsoring NCT01980212?

NCT01980212 is sponsored by Hunan Province Tumor Hospital.

What condition does NCT01980212 study?

NCT01980212 studies Advanced Non-small Cell Lung Cancer, First Line Treatment, Thioredoxin Reductase Activity, Carcinoembryonic Antigen, Progression.

Is NCT01980212 still recruiting?

NCT01980212 is currently completed. Last updated 26 March 2020.

Last reviewed 2020-03-26 · How we verify

NCT01980212

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer

Completed Last updated 26 March 2020

What this trial tests

trial in Advanced Non-small Cell Lung Cancer in 500 participants. Completed in 1 December 2018.

Timeline

1 May 2013

Primary endpoint
1 December 2016

1 December 2018

Quick facts

Lead sponsor	Hunan Province Tumor Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 May 2013
Primary completion	1 December 2016
Estimated completion	1 December 2018
Sites	1 location across China

Conditions studied

Advanced Non-small Cell Lung Cancer — all drugs for Advanced Non-small Cell Lung Cancer →
First Line Treatment — all drugs for First Line Treatment →
Thioredoxin Reductase Activity — all drugs for Thioredoxin Reductase Activity →
Carcinoembryonic Antigen — all drugs for Carcinoembryonic Antigen →

Sponsor

Hunan Province Tumor Hospital

Who can join

Adults 18 to 80, any sex, with Advanced Non-small Cell Lung Cancer or First Line Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In pre-clinical study we found that the thioredoxin reductase activity of serum harbours huge difference between cancer patients and non-cancer patients, the enzyme activity elevated remarkably among cancer patients, and after any kind of treatment serum thioredoxin reductase activity declined remarkably, so we hypothesis that serum thioredoxin reductase activity could be a warning marker for early progression of first-line treatment for advanced non-small cell lung cancer

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Thioredoxin (Trx): A redox target and modulator of cellular senescence and aging-related diseases.
Yang B, Lin Y, Huang Y, Shen YQ, et al · · 2024 · cited 39× · PMID 38232457 · DOI 10.1016/j.redox.2024.103032
Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.
Akter S, Madhuvilakku R, Kar AK, Nila IS, et al · · 2026 · PMID 41881983 · DOI 10.1038/s41392-026-02583-x

Verify or expand the search:

Other recruiting trials for Advanced Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT06868732 — Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC · Phase 1 · recruiting
NCT06452277 — A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Particip · Phase 3 · recruiting
NCT06269133 — Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non- · active not recruiting
NCT06043973 — Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance · Phase 3 · recruiting
NCT05416775 — Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Other Hunan Province Tumor Hospital trials

Trials by the same sponsor.

NCT06706219 — Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unres · Phase 2 · not yet recruiting
NCT07001995 — Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression · Phase 2 · not yet recruiting
NCT07477808 — Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07251582 — Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01980212 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hunan Province Tumor Hospital
Last refreshed: 26 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01980212.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing